Secernin-2 Stabilizes Histone Methyltransferase KMT2C to Suppress Progression and Confer Therapeutic Sensitivity to...

Triple-negative breast cancer (TNBC) represents a significant clinical challenge because it lacks the estrogen, progesterone, and HER2 receptors typically targeted in other breast cancer subtypes. Prior research has shown that the absence of these receptors necessitates the identification of novel molecular drivers to improve patient outcomes and therapeutic efficacy. Epigenetic regulators and histone methyltransferases often play diverse roles in modulating the transcriptional landscape of aggressive malignancies by altering chromatin accessibility at specific gene loci. Histone-lysine N-methyltransferase 2C (KMT2C) serves as a critical enzyme for H3K4 monomethylation, which influences the activation of enhancers and subsequent gene expression patterns across the genome. The stability of such proteins is frequently governed by complex ubiquitin-proteasome pathways or autophagic degradation mechanisms that respond to cellular stress or metabolic shifts. Loss of these regulatory enzymes can lead to the silencing of tumor-suppressive genes and the activation of oncogenic pathways. This absence of evidence motivated the current investigation into uncharacterized genes that might regulate these epigenetic factors to suppress TNBC progression and enhance drug sensitivity.

This investigation evaluates the functional role of secernin 2 (SCRN2) as a potential tumor suppressor within the context of triple-negative breast cancer. Researchers sought to determine how SCRN2 expression levels correlate with patient prognosis and the overall survival of individuals diagnosed with this aggressive subtype. The study explores the specific biochemical interactions between SCRN2 and the histone methyltransferase KMT2C to understand protein stabilization mechanisms in the nucleus. Scientists aimed to delineate the downstream signaling pathways, specifically focusing on Bcl2-modifying factor (BMF) and its role in inducing intrinsic apoptosis through mitochondrial pathways. Another objective involved assessing whether SCRN2 modulation could enhance the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors by altering DNA repair gene expression and inducing genomic instability. The team investigated these relationships through both in vitro cell line models and in vivo xenograft experiments to ensure biological relevance and clinical translatability. By identifying the molecular targets of SCRN2, the researchers hoped to uncover new vulnerabilities in TNBC cells that could be exploited for therapeutic gain.

The experimental design utilized human triple-negative breast cancer cell lines to perform gain-of-function and loss-of-function assays via lentiviral transduction of specific genetic constructs. Protein stability and degradation pathways were analyzed using cycloheximide chase assays and treatments with proteasome or autophagy inhibitors to pinpoint the metabolic fate of SCRN2. Co-immunoprecipitation (Co-IP) experiments identified the physical interaction between SCRN2, Bcl2-associated athanogene 2 (BAG2), and the E3 ubiquitin-protein ligase CHIP within the cellular proteome. Chromatin immunoprecipitation (ChIP) followed by quantitative polymerase chain reaction (qPCR) measured the enrichment of histone H3 monomethylation at lysine 4 (H3K4me1) at the BMF enhancer region. Flow cytometry with Annexin V/PI staining quantified the induction of intrinsic apoptosis following SCRN2 overexpression or KMT2C knockdown in various TNBC backgrounds. In vivo tumor growth was monitored in mouse xenograft models to evaluate the impact of SCRN2 on cancer progression and PARP inhibitor sensitivity over a multi-week observation period. Statistical analyses including Kaplan-Meier survival curves were employed to correlate SCRN2 expression levels with clinical outcomes in breast cancer patient datasets.

Secernin 2 (SCRN2) functions as a novel tumor suppressor that significantly inhibits the proliferation and migration of triple-negative breast cancer cells in culture. Data revealed that SCRN2 is frequently downregulated in TNBC tissues through chaperone-mediated autophagic degradation, a process linked to diminished patient survival rates in clinical cohorts. The protein stabilizes KMT2C by recruiting BAG2, which effectively blocks the interaction between KMT2C and the E3 ligase CHIP to prevent proteasomal degradation and maintain methyltransferase activity. Enhanced KMT2C stability leads to increased H3K4me1 levels at the Bcl2-modifying factor (BMF) enhancer, resulting in the transcriptional activation of this pro-apoptotic protein. Knockdown of KMT2C successfully reversed the inhibitory effects of SCRN2 on tumor progression in both laboratory and animal models, confirming the dependency of the phenotype on this enzyme. SCRN2 expression reduced the levels of DNA repair-related genes, thereby increasing endogenous DNA damage and sensitizing cells to PARP inhibition through synthetic lethality mechanisms. These results demonstrate that the SCRN2-KMT2C axis is a critical determinant of TNBC cell survival and response to DNA-damaging therapies.

These findings establish SCRN2 as a pivotal regulator of the epigenetic landscape in triple-negative breast cancer through its stabilization of KMT2C. Restoring SCRN2 levels or mimicking its downstream effects offers a promising strategy for overcoming the therapeutic bottlenecks associated with TNBC treatment resistance. The identification of the SCRN2-BAG2-KMT2C axis provides a specific molecular target for developing new pharmacological interventions aimed at restoring tumor suppressive pathways. Future clinical applications may involve using SCRN2 expression as a biomarker to predict patient responsiveness to PARP inhibitors in personalized medicine frameworks. The study highlights the importance of chaperone-mediated autophagy in controlling the abundance of tumor suppressors in mammary malignancies and other solid tumors. This research opens new avenues for exploring how histone methyltransferase stability influences the sensitivity of cancer cells to DNA-damaging agents and targeted therapies. Ultimately, the work underscores the potential of targeting protein degradation pathways to enhance the efficacy of existing cancer treatments.